Eli Lilly reports that its investigational “triple-G” weight-loss and diabetes drug, retatrutide, outperforms Novo Nordisk’s Ozempic in a head-to-head study. Multiple outlets describe Lilly’s results as showing greater reductions in blood sugar and more weight loss, using comparisons against Ozempic’s highest or standard dosing in the trial.
The coverage focuses on effectiveness and how it is measured. Some outlets highlight weight loss as the headline outcome, while others also emphasize diabetes endpoints and safety trade-offs. BioPharma Dive notes that the higher-performing retatrutide arm is linked to increased side effect rates and more treatment discontinuations. STAT frames the trial as a broad head-to-head comparison, while Business Insider leads with the scale of weight-loss differences.
Overall, all accounts present Lilly’s announcement of better efficacy than Ozempic, with differences mainly in what they foreground—weight loss versus metabolic outcomes—and how prominently they mention tolerability and discontinuations.
